IBC Research Fdn retweetledi

Results from @TheTBCRC 049 trial of tucatinib/cape/trastuzumab for HER2+ LMD now published in @NatureCancer. Most patients had improved neurological deficits, PFS was 4.4 months and OS 10 months, with 41% of patients alive at 18 months. nature.com/articles/s4301…

English























